KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Liabilities and Shareholders Equity (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $90.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 2.77% to $90.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $182.5 billion, a 36.05% decrease, with the full-year FY2025 number at $90.0 billion, down 2.77% from a year prior.
  • Liabilities and Shareholders Equity was $90.0 billion for Q4 2025 at Bristol Myers Squibb, down from $92.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $112.4 billion in Q1 2021 to a low of $90.0 billion in Q4 2025.
  • A 4-year average of $99.9 billion and a median of $98.6 billion in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: dropped 11.66% in 2021, then dropped 2.77% in 2025.
  • Bristol Myers Squibb's Liabilities and Shareholders Equity stood at $109.3 billion in 2021, then fell by 11.43% to $96.8 billion in 2022, then decreased by 4.36% to $92.6 billion in 2024, then decreased by 2.77% to $90.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Liabilities and Shareholders Equity are $90.0 billion (Q4 2025), $92.4 billion (Q1 2025), and $92.6 billion (Q4 2024).